Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Artelo Biosciences Inc

ARTL ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: N/A

Last Close

$3.83

▼ -5.20%

Market Cap $2.10M · Vol 10.26K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$2.10M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

41.77

Momentum

Beta

0.00

vs Market

52W High

$178.83

97.86% below

52W Low

$3.49

9.74% above

Volume

10.26K

Avg 133.10K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

99.94%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Artelo Biosciences Inc (ARTL) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ARTL pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-25.92%

-37.77%

-61.31%

-94.57%

YTD

-88.37%

-97.02%

-98.38%

-99.80%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-12,879,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-343.49% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	547.77K

Technical Indicators

50-Day SMA	$6.08
200-Day SMA	$25.74
RSI (14)	41.77
Beta	0.00
52-Week High	$178.83
52-Week Low	$3.49

Volume Today	10.26K
Avg Daily Volume (30D)	133.10K
Relative Volume	0.08x
Volatility (10D)	342.02
Volatility (30D)	229.78
Free Float	99.94%

Analyst Consensus

N/A

Current Price $3.83

Mean Target N/A

52W Low$3.49 52W High$178.83

Current

Target

$3.49 $178.83

Current Analyst target

· 0 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00793XCX9

ISINUS04301G8050

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +3.56% ARGX.BR argenx SE -0.61% ARGX argenx SE -2.39% 2269.HK WuXi Biologics (Cayman) Inc. +4.77% INSM Insmed Incorporated -4.86%

Company Profile

Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutics that modulate lipid-signaling pathways. The Company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.